Loading
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
NASDAQHealthcareBiotechnology
Latest quote
$13.00
+$0.76 · +6.21%
Previous close
$13.00
+$0.76 · +6.21%
Regular session · ET · Market data may be delayed.
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Day range
Current $13.00
52-week range
Current $13.00
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$37.00
184.62% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Schwab U.S. Small-Cap ETFSCHA2.96M0.01%21.82B USD0.03%$32.79+0.40%
Guggenheim Funds Trust - Guggenheim Securitized Income ETFGISC1.18M0.09%67.9M USD0.47%$49.2511+0.08%
Guggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSH1.18M0.03%145.5M USD0.25%$49.85+0.02%
iShares Core S&P Total U.S. Stock Market ETFITOT756.76K0.00%98.09B USD0.03%$169.66+0.64%
Schwab U.S. Broad Market ETFSCHB350.02K0.00%45.38B USD0.03%$29.91+0.61%
Fidelity Nasdaq Composite Index ETFONEQ201.79K—10.94B USD0.21%$107.81+0.63%
T. Rowe Price Innovation Leaders ETFTNXT7.77K0.04%19.67M USD0.49%$29.155+1.22%Schwab U.S. Small-Cap ETFSCHAGuggenheim Funds Trust - Guggenheim Securitized Income ETFGISCGuggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSHiShares Core S&P Total U.S. Stock Market ETFITOTSchwab U.S. Broad Market ETFSCHBFidelity Nasdaq Composite Index ETFONEQT. Rowe Price Innovation Leaders ETFTNXTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
